As of 1:31 p.m. on October 23, shares of Green Cross were trading at 268,000 KRW, up 16.52% from the previous day. The trading volume stood at 1,325,840 shares, which is 150.46% of the previous day's volume. Green Cross is known as a pharmaceutical company specializing in blood products and vaccines.
On October 23, Lee Hyerin, a researcher at KTB Investment & Securities, stated, "The signing of a COVID-19 vaccine CMO agreement with CEPI (Coalition for Epidemic Preparedness Innovations) is a surprise development. Additional CMO agreements with multiple global pharmaceutical companies are expected in the future. While it is difficult to guarantee long-term sustainability for the COVID-19 vaccine business, it is expected to serve as a cash cow in the short to medium term." She set the target price for Green Cross at 300,000 KRW.
Over the past five days, individual investors made a net purchase of 38,342 shares of Green Cross. Foreign investors made a net purchase of 3,933 shares, while institutional investors made a net sale of 39,211 shares.
※ Source: AI investment assistant AI Rassiro
※ This article was automatically generated in real time by a news generation algorithm jointly developed by Asia Economy and ThinkPool, a financial AI specialist company.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
